Which are the causes of Alkaptonuria?

Alkaptonuria is a rare metabolic disorder caused by a deficiency of the enzyme homogentisate 1,2-dioxygenase (HGD), which prevents the body from properly breaking down the amino acids tyrosine and phenylalanine. This leads to an accumulation of homogentisic acid in the body, which deposits as a dark pigment in connective tissues, eventually causing cartilage damage and joint pain.

What is the genetic cause of Alkaptonuria?

Alkaptonuria is inherited in an autosomal recessive pattern, meaning an individual must inherit two mutated copies of the HGD gene—one from each parent—to develop the condition. The HGD gene is located on chromosome 3 (3q13.33). When this gene is mutated, the HGD enzyme cannot function efficiently. Without this functional enzyme, homogentisic acid builds up and is excreted in the urine, turning it dark or black upon exposure to air, a hallmark sign of Alkaptonuria.

How does the metabolic mechanism work?

Think of your metabolism as a conveyor belt designed to break down specific proteins. In a person with Alkaptonuria, the "machine" (the HGD enzyme) responsible for processing homogentisic acid is broken. Because the belt cannot process this substance, it "overflows" and accumulates in the body. This process, known as ochronosis, involves the following complications:

• Joint Damage: Accumulation of pigment causes cartilage to become brittle and prone to degeneration.


• Pigmentation: The skin, eyes, and ears may take on a bluish-black tint due to pigment deposits.


• Urine Changes: Homogentisic acid oxidizes when exposed to oxygen, causing urine to turn black.


• Systemic Effects: Long-term buildup can lead to heart valve issues and kidney stones.

Are there environmental triggers for Alkaptonuria?

Alkaptonuria is strictly a genetic, metabolic disorder, not an environmental one. There are no known infectious or autoimmune triggers that cause Alkaptonuria. While the severity of symptoms may be influenced by lifestyle factors—such as physical stress on joints—the underlying etiology is entirely determined by the genetic mutation inherited at conception.

What is the focus of current research?

Current research into Alkaptonuria is focused on Nitisinone, a medication that inhibits the production of homogentisic acid by blocking an enzyme further "upstream" in the metabolic pathway. Researchers are studying how early intervention with this treatment can prevent the long-term, irreversible joint damage that defines the disease.

Next steps

• Consult a metabolic specialist or geneticist for definitive diagnostic testing of the HGD gene.


• Join the 31 community members at DiseaseMaps.org to share experiences and coping strategies.


• Monitor for early signs of joint pain and discuss potential treatments like Nitisinone with your physician.

Medical Disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Alkaptonuria overview.


• Orphanet: Rare disease database entry for Alkaptonuria (ORPHA:67).


• OMIM (Online Mendelian Inheritance in Man): HGD gene entry (#203500).


• Alkaptonuria Society: Patient resources and clinical research updates.